Skip to main content

Institute for Neurological Discoveries

IND > Neurodegenerative Disorders Division

Neurodegenerative Disorders Division Overview

couple

Neurodegenerative diseases arise as particular brain regions gradually fail. They are clinically characterized by the nature of the symptoms that first present, and usually manifest as changes in cognition, movement, strength, or balance.


The Neurodegenerative Disorders Division focuses on a variety of diseases, which can be divided into four groups:


Neurodegenerative Disorders Division Investigators

Abdulbaki Agbas, MSc, PhD, Department of Biochemistry - KCMB
Dora Agbas
, PhD, Molecular and Integrative Physiology
Richard Barohn, MD, Neurology
Andrei Belousov, PhD, Molecular and Integrative Physiology
Amanda Bruce, PhD, Hoglund Brain Imaging Center
Jeff Burns, MD, MS, Neurology
Merlin Butler, MD, PhD, Psychiatry and Behavioral Sciences
In-Young Choi, PhD, Hoglund Brain Imaging Center
Julie Christianson, PhD, Anatomy and Cell Biology
Mazen Dimachkie, MD, Neurology
Richard Dobrowsky, PhD, Pharmacology, Toxicology and Therapeutics
Richard Dubinsky, MD, MPH, Neurology
Barry Festoff, MD, Neurology and Pharmacology - VAMC
Paige Geiger
, PhD, Molecular and Integrative Physiology
Randal Halfman, PhD, Molecular and Integrative Physiology - Stowers
Nancy Hammond, MD, Neurology
Michael Johnson, PhD, Chemistry - KU
Patricia Kluding, PT, PhD, SAH Physical Therapy Rehabilitation Sciences
Jeff Krise, PhD, Pharmaceutical Chemistry - KU
Robb Krumlauf, PhD, Anatomy and Cell Biology - Stowers
Phil Lee, PhD, Hoglund Brain Imaging Center
Steven Levine, PhD, Molecular and Integrative Physiology
Wen Liu, PhD, SAH Physical Therapy Rehabilitation Sciences
Sharon Lynch, MD, Neurology
Kelly Lyons, PhD, Neurology
Kenneth McCarson, PhD, Pharmacology, Toxicology and Therapeutics
Elias Michaelis, MD, PhD, Pharmacology, Toxicology and Therapeutics - KU
Mary Michaelis, PhD, Pharmacology, Toxicology and Therapeutics - KU
Nancy Muma, PhD, Pharmacology, Toxicology and Therapeutics
Jules Nazzaro, MD, Surgery Neurosurgery
Andrea Nicol, MD, Anesthesiology
Hiroshi Nishimune, PhD, Anatomy and Cell Biology
Rajesh Pahwa, MD, Neurology
Mamatha Pasnoor, MD, Neurology
Alan Reeves, MD, Radiology
Michael Salacz, MD, Neuro-Oncology, Medical Oncology
Kausik Si, PhD, Molecular and Integrative Physiology
Peter Smith,  PhD, KIDDRC
John Stanford, PhD, Molecular and Integrative Physiology
Russell Swerdlow, MD, Neurology
Sarah Taylor, MD, Hematology/Oncology
Fen Wang, MD, PhD, Radiation/Oncology
WenFang Wang, PhD, SAH Physical Therapy Rehabilitation Sciences
Yunxia Wang, MD, Neurology
Doug Wright, PhD, Anatomy and Cell Biology
C. Ron Yu, PhD, Anatomy and Cell Biology
Hao Zhu, PhD, SAH Physical Therapy Rehabilitation Sciences


Last modified: Aug 27, 2018
Division directors

Division Director:
Russ Swerdlow, MD

Associate Director:
Doug Wright, PhD

Research Goals

Our goal is to develop treatments that can arrest the progression of neurodegenerative diseases in affected persons and develop interventions to protect those at risk of developing a particular neurodegenerative disease.

Frequently Asked Questions


If you are experiencing symptoms and would like to make an appointment with a doctor, call 913-588-6820.

ID=x8176